FluMist, which was initially approved in 2023, is indicated for individuals from two to 49 years old. Those who want to ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

The FluMist vaccine, manufactured by AstraZeneca, had previously been approved back in 2003 to be given by health care ...

AstraZeneca’s new U.S. spending also leaves in doubt the pharmaceutical company’s plans to invest in a vaccine site in ...

LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...

The US Food and Drug Administration (FDA) has approved the first self-administered seasonal influenza vaccine - AstraZeneca’s FluMist. FluMist has been available in the US since 2003 ...

You may report side effects related to AstraZeneca products. FLUMIST is a live attenuated influenza vaccine (LAIV), which is administered as a nasal spray for the prevention of influenza.

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

(Alliance News) - AstraZeneca PLC on Friday announced that its influenza vaccine FluMist has been approved for self-administration in the US. The Cambridge, England-based biopharmaceutical company ...

The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...